Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
NCT01347788
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
34
Enrollment
OTHER
Sponsor class
Conditions
Prostate Adenocarcinoma
Interventions
DRUG:
cabozantinib
Sponsor
Massachusetts General Hospital